Glofitamab for mantle cell lymphoma after CAR T-cell therapy
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called glofitamab for people with mantle cell lymphoma (MCL) whose cancer did not respond or came back after CAR T-cell therapy. Glofitamab is a type of immunotherapy that helps your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mantle cell lymphoma (MCL) that did not respond or returned after CAR T-cell therapy.
- You are at least 18 years old.
- You have acceptable kidney and liver function.
- You have adequate blood cell counts (or low counts due to lymphoma in the bone marrow).
- You have no ongoing severe nerve problems from the CAR T-cells.
- You can attend study visits and follow the schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests how well two anti-cancer medicines—glofitamab and pirtobrutinib—work for mantle cell lymphoma (MCL) that has not responded well to prior BTK inhibitor therapy. It may help by shrinking the lymphoma after earlier treatment and checking how safe the combination is for people with similar disease history.
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
This trial tests a combination of three drugs (glofitamab, ibrutinib, and obinutuzumab) for people with untreated mantle cell lymphoma. The goal is to see if this combination works better for high-risk or older patients.
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
This trial tests a combination of three drugs (glofitamab, orelabrutinib, and bortezomib) for people with high-risk mantle cell lymphoma. The goal is to see if the combination works better than standard treatments, and it may be an option if your lymphoma has not responded well or has certain aggressive features.
This trial tests a new drug, glofitamab, for mantle cell lymphoma that came back or didn’t respond after CAR-T cell therapy. It aims to see if glofitamab can shrink or control the lymphoma.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.